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Abstract
The abundance of lysozyme on mucosal surfaces suggests that successful colonizers must be able to evade its antimicrobial
effects. Lysozyme has a muramidase activity that hydrolyzes bacterial peptidoglycan and a non-muramidase activity
attributable to its function as a cationic antimicrobial peptide. Two enzymes (PgdA, a N-acetylglucosamine deacetylase, and
Adr, an O-acetyl transferase) that modify different sites on the peptidoglycan of Streptococcus pneumoniae have been
implicated in its resistance to lysozyme in vitro. Here we show that the antimicrobial effect of human lysozyme is due to its
muramidase activity and that both peptidoglycan modifications are required for full resistance by pneumococci. To examine
the contribution of lysozyme and peptidoglycan modifications during colonization of the upper respiratory tract,
competition experiments were performed with wild-type and pgdAadr mutant pneumococci in lysozyme M-sufficient
(LysM
+/+) and -deficient (LysM
2/2) mice. The wild-type strain out-competed the double mutant in LysM
+/+, but not LysM
2/2
mice, indicating the importance of resistance to the muramidase activity of lysozyme during mucosal colonization. In
contrast, strains containing single mutations in either pgdA or adr prevailed over the wild-type strain in both LysM
+/+ and
LysM
2/2 mice. Our findings demonstrate that individual peptidoglycan modifications diminish fitness during colonization.
The competitive advantage of wild-type pneumococci in LysM
+/+ but not LysM
2/2 mice suggests that the combination of
peptidoglycan modifications reduces overall fitness, but that this is outweighed by the benefits of resistance to the
peptidoglycan degrading activity of lysozyme.
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Introduction
For many pathogens, colonization of mucosal surfaces is a
prerequisite for events leading to disease. At these sites the host
elaborates numerous antimicrobial factors that may reduce the
burden of colonizing organisms. Lysozyme, a prominent member
of these antimicrobials, is found in high concentrations (.500 mg/
ml) in mucosal surface fluids such as those lining the upper
respiratory tract [1]. Lysozyme is expressed by the epithelia and is
also a major component of the granules of neutrophils, which may
be recruited when the mucosa is acutely inflamed [2,3,4].
Lysozyme has two distinct antibacterial activities [5,6]. Its
enzymatic muramidase activity hydrolyzes the conserved ß-1,4
glycosidic bond between N-acetyl glucosamine (GlcNAc) and N-
acetyl muramic acid (MurNAc), the disaccharide residues of the
peptidoglycan backbone. Hydrolysis of the glycan strands leads to
degradation of the cell wall and bacterial lysis. In addition, an
antibacterial activity is observed with catalytically inactive
lysozyme [6]. This non-muramidase activity has been attributed
to the disruption of bacterial membrane function by an inherent
nine amino acid cationic antimicrobial peptide (CAMP) [5,7].
The contribution of lysozyme to innate host defense has been
analyzed in genetically- modified mice. Over-expression of rat
lysozyme in the lungs of transgenic mice was associated with
enhanced killing of group B streptococci and Pseudomonas aeruginosa
[8]. Mice have two different lysozyme genes, LysM, expressed by
myeloid and epithelial cells and LysP, expressed by Paneth cells in the
gut. LysM
2/2 mice show defective clearance of P. aeruginosa [9] and
Klebsiella pneumoniae from their lower airways [3]. While these studies
demonstrate a protective role of lysozyme for opportunistic pathogens
in normally sterile sites, its impact on the mucosal flora is unknown.
Another consideration is that bacteria modify the glycan backbone
of their peptidoglycan, and these modifications may affect their
sensitivity to lysozyme [10,11,12,13,14,15,16,17,18,19]. In Staphylo-
coccus aureus,f o re x a m p l e ,O-acetylation at position C-6 on MurNAc
and D-alanine esters on its cell wall-linked teichoic acid have an
additive effect on resistance to muramidase and non-muramidase
activities of lysozyme in vitro [13]. Organisms that reside on mucosal
surfaces where lysozyme is particularly abundant must have the
ability to evade its antibacterial effects. However, the contribution of
cell wall modifications, which affect lysozyme resistance, to bacterial
survival on mucosal surfaces has not been examined.
Streptococcus pneumoniae (the pneumococcus) is a leading extracel-
lular Gram-positive pathogen that commonly colonizes the human
nasopharynx. Although colonization is generally asymptomatic,
infection induces an acute inflammatory response characterized by a
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capsular polysaccharide (CPS) covalently attached to its cell wall
[20], it is capable of evading phagocytic clearance and causing
invasive disease. Two enzymes have been associated with lysozyme
resistance in S. pneumoniae: peptidoglycan N-acetylglucosamine
deacetylase (PgdA) [10] and attenuator of drug resistance (Adr),
whichisanO-acetyltransferase[21].Theseproteinsmodifyaportion
of the glycan residues; PgdA deacetylates GlcNAc (40–80% of
GlcNAc residues, ,10% of MurNAc residues) and Adr acetylates
MurNAc [10,21,22]. Previous studies have shown that mutations in
either of these genes are sufficient to increase sensitivity to chicken
egg lysozyme in vitro [10,21,22]. Systemic infection of mice with a
pgdA strain was associated with decreased virulence, although the
role of lysozyme resistance in this effect was not established [22].
In this study, we determine the contribution of lysozyme to
bacterial colonization using a murine model of carriage by S.
pneumoniae. Our findings demonstrate the critical role of lysozyme,
and peptidoglycan modifications that affect resistance to its
muramidase activity, in dictating the composition of the microflora
of the mucosal surface of the upper airway.
Results
Peptidoglycan modifications affect sensitivity to human
lysozyme
To test the effects of peptidoglycan modifications, defined
mutations were made in pgdA and adr in the pneumococcal strain
TIGR4basedonthegenomicinformationavailableforthisisolateas
described in the Methods. Figure 1 depicts the locations of O-
acetylation (Adr) and N-deacetylation (PgdA) relative to the
glycosidic linkage of MurNAc and GlcNAc that is hydrolyzed by
lysozyme. The wild-type (WT), pgdA, adr,a n dpgdAadr strains showed
equivalent growth characteristics in broth culture during log phase.
Addition of chicken egg lysozyme (100 mg/ml) to mid-log phase
cultures led to arrested growth for the pgdA mutant strains (pgdA and
pgdAadr), but not the WT or adr strains (Fig. 2A). Growth arrest
occurred morepromptly for the pgdAadr than pgdA mutant suggesting
a synergistic effect of the two genes on sensitivity to lysozyme. The
results with the pgdA mutant were consistent with previous studies
[10,22], however the adr mutant of strain TIGR4 generated in this
study did not have increased sensitivity to lysozyme as has been
previously reported for a strain derived from R6 [21]. A similar
pattern of sensitivity was observed using recombinant human
lysozyme (100 mg/ml), although with the human enzyme bacterial
lysis was more apparent (Fig. 2B). Purified insoluble peptidoglycan
from each strain was tested to determine whether the effect of
lysozyme on cultures correlated with its hydrolytic activity. For both
chicken egg (Fig. 3A) and human lysozyme (Fig. 3B) only
peptidoglycan from the mutants lacking pgdA were hydrolyzed. As
with whole bacteria, peptidoglycan from the pgdAadr mutant showed
greater sensitivity to lysozyme than the pgdA strain.
Pneumococcalgrowthischaracterizedbyspontaneousautolysisin
stationary phase because of the endogenous expression of its major
amidase, LytA (Fig. 1). Since colonies of pgdA mutants generated in
this study appeared more autolytic based on colony morphology, the
in vitro effects of lysozyme were tested in a lytA background (Fig. 4).
To determine the effect of lysozyme on pneumococcal survival,
viable counts were measured five hours after addition of chicken egg
(Fig.4A) orhuman lysozyme(Fig.4B) tomid-log phasecultures.The
WT strain and adr mutant showed no loss of viability. Survival of
both pgdA mutants was significantly reduced by treatment with
chicken egg lysozyme, with a more significant effect on the pgdAadr
mutant. Only the pgdAadr mutant showed a significant decrease in
survival following treatment with human lysozyme. The estimated
MBC50 (mean concentration required for 50% killing) for human
lysozyme exceeded 180 mg/ml for the WT and adr mutant (Table 1).
In contrast, the MBC50 was only 50 to 100 mg/ml for the pgdA
mutant and 12.5 to 25 mg/ml for the pgdAadr mutant. It was
concluded that there is a combined effect of peptidoglycan
modifications by PgdA and Adr on resistance to human lysozyme.
Author Summary
For many successful pathogens, their surfaces must be
able to adapt to different host environments, or to avoid
host immune components, to establish infection. Bacterial
pathogens, for example, are known to modify their cell
walls, which are comprised largely of peptidoglycan. Our
study focuses on peptidoglycan modifications by Strepto-
coccus pneumoniae, which initiates interaction with its host
by colonizing the mucosal surface of the upper respiratory
tract. Two proteins (PgdA and Adr) that modify the cell
wall of S. pneumoniae have each been associated with
resistance to lysozyme, which cleaves peptidoglycan and is
one of the most abundant antimicrobial factors in the
human respiratory tract. Using defined bacterial mutants
together with mice that express or lack lysozyme, we show
that the full resistance to lysozyme requires modifications
by both proteins. These cell wall modifications each come
at a significant fitness cost to the bacterium. This fitness
cost, however, is outweighed by the benefits of lysozyme
resistance in vivo. Our study, therefore, demonstrates the
relationship between a bacterial pathogen and a host
defense mechanism that imparts a substantial selective
pressure on organisms that colonize the mucosal surface.
Figure 1. Predicted peptidoglycan structure. PgdA, an N-acetyl
glucosamine, and Adr, an O-acetyltransferase, modify the MurNAc-
GlcNAc disaccharide structure at the indicated sites. The major
pneumococcal autolysin, LytA, cleaves the stem peptide attached to
MurNAc. Lysozyme hydrolyzes the glycosidic bond between MurNAc
and GlcNAc as shown.
doi:10.1371/journal.ppat.1000241.g001
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muramidase activity of lysozyme
To test whether these effects were due to the muramidase
activity of lysozyme, the enzyme was inactivated by treatment at
100uC for 60 min, which are conditions that allow lysozyme to
retain its non-muramidase activity [5,13]. Hydrolysis assays with
purified peptidoglycan were used to confirm the loss of
muramidase activity. The human, but not chicken egg enzyme,
showed complete inactivation under these conditions (data not
shown). Therefore, inactivated human lysozyme was tested for its
effects on bacterial viability (Fig. 4B). The denatured enzyme
lacked anti-pneumococcal activity against all of the strains tested.
There was also no effect on survival when the LP9 peptide, which
has been shown to confer the non-muramidase CAMP activity of
lysozyme, was substituted for the intact enzyme in these viability
assays at concentrations up to 200 mg/ml (data not shown). It was
concluded that the combined effect of modifications by PgdA and
Adr on resistance to human lysozyme is due to its muramidase,
rather than its non-muramidase activity.
Peptidoglycan modifications are required for lysozyme
resistance in vivo
The lytA
+ strains characterized in vitro were used to test the
hypothesis that lysozyme limits colonization of mucosal surfaces.
Both lysozyme sensitive (pgdAadr) and resistant (WT) pneumococci
were able to colonize the upper respiratory tract of the mouse
(data not shown). To examine more subtle differences in bacterial
fitness, competition experiments were used to assess the relative
ability of these strains to colonize the nasopharynx. Three days
after intranasal inoculation with equivalent numbers of the WT
strain and the pgdAadr mutant, the density of colonization of each
strain was measured in nasal lavages to determine the competitive
index. Prior to in vivo experiments we confirmed there was no effect
of one strain on another during in vitro co-cultivation experiments
(data not shown). As expected, the lysozyme-resistant WT strain
out-competed the lysozyme-sensitive pgdAadr mutant in lysozyme-
expressing mice (Fig. 5A). To confirm that the effect on
colonization was due specifically to the mutations introduced into
pgdA and adr, we generated corrected strains by transformation
with WT genomic DNA followed by selection in the presence of
lysozyme. Like the WT strain, the pgdA+adr+ revertant was able to
out-compete the pgdAadr mutant in lysozyme-expressing hosts
(Fig. 5B). Together these results demonstrated that pneumococci
Figure 2. Effect of peptidoglycan modifying enzymes PgdA and Adr on growth of pneumococci in the presence or absence of
lysozyme. Growth characteristics of the wild-type (WT) strain or defined mutants were compared by following the optical density (OD 620 nm).
Once the broth culture reached mid-log phase, lysozyme (100 mg/ml) was added where indicated by an arrow. A) chicken egg lysozyme (+L) or B)
recombinant human lysozyme (+Hu L). Graphs are representative of six independent experiments.
doi:10.1371/journal.ppat.1000241.g002
Table 1. Sensitivity to recombinant human lysozyme.
Strain MBC50 (mg/ml)
WT .180
adr2. 180
pgdA2 50–100
pgdA2 adr2 12.5–25
Sensitivity is shown by the estimated MBC50 (mean bactericidal concentration)
of the wild-type (WT) strain and defined mutants. Strains tested were in a lytA
background to eliminate effects of autolysis. Ranges were based on three
independent determinations.
doi:10.1371/journal.ppat.1000241.t001
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able to persist during colonization.
To define the contribution of lysozyme during colonization,
competition experiments were carried out in congenic LysM
2/2
mice. In lysozyme-deficient hosts, unlike the lysozyme-sufficient
hosts, the pgdAadr mutant prevailed over the WT or pgdA+adr+
revertant (Fig. 5A and B). This observation demonstrated that the
survival advantage conferred by these two peptidoglycan modifi-
cations requires lysozyme expression by the host. Moreover,
without the expression of lysozyme, pneumococci that do not
modify their peptidoglycan show a survival advantage during
colonization. This suggests that the combined modifications by
PgdA and Adr result in an in vivo fitness cost, but that this fitness
cost is outweighed by their contribution to lysozyme resistance.
In contrast to the results with the pgdAadr mutant, single mutants
in pgdA or adr out- competed the WT strain in both LysM
+/+ and
LysM
2/2 mice (Fig. 5C and D). This suggests that individual
modifications by either PgdA or Adr confer a fitness cost on the
organism regardless of the presence of lysozyme. A further
implication is that the combined effects of both modifications are
required to confer a survival benefit – an advantage to the
organism seen in lysozyme-sufficient, but not -deficient, hosts
corresponding to the increased resistance of the WT strain to the
muramidase activity of lysozyme.
Epithelium is the source of upper airway lysozyme
To ascertain the source of upper airway lysozyme that effects
colonization, we considered the contributions of the epithelia or
the influx of neutrophils in response to pneumococci.
To evaluate the role of neutrophil-derived lysozyme, neutrophil-
enriched peritoneal exudates were isolated from LysM
+/+ and
LysM
2/2 mice and used in ex vivo killing assays. The WT strain
and pgdA, adr, and pgdAadr mutants were equally resistant to killing
by these cells whether derived from LysM
+/+ or LysM
2/2 mice
(data not shown). Because strain TIGR4 is relatively resistant to
neutrophils obtained from mice, human neutrophils were also used
in killing assays (Fig. 6A). In comparison to the WT strain, mutants
in pgdA (pgdA and pgdAadr) were significantly more resistant to
neutrophil-mediated killing. Correction of the mutation in pgdA
(pgdA+adr2 and pgdA+adr+) eliminated increased resistance to
killing by human neutrophils. Thus, the pgdAadr mutant was less
resistant to lysozyme but more resistant to killing by human
neutrophils, making it unlikely that the anti-pneumococcal activity
of neutrophils was mediated by lysozyme. This also indicated that
peptidoglycan modification by PgdA has lysozyme-independent
effects on neutrophil-mediated pneumococcal killing. Additional
evidence that neutrophil activity was not contributing to lysozyme-
dependent differences among strains came from competition
experiments in which mice were depleted of neutrophils.
Administration of the monoclonal antibody RB6-8C5, which
targets Ly6G-expressing cells (or rat IgG control), to LysM
+/+ mice
prior to bacterial challenge had no effect on the ability of the
lysozyme-resistant WT strain to out-compete the lysozyme-
sensitive pgdAadr mutant (Fig. 6B).
The source of lysozyme in nasal lavages was also examined
using an antibody to the mouse enzyme. Lysozyme M was
detected in Western blots on lavage samples from LysM
+/+ but not
LysM
2/2 colonized mice (Fig. 7A). Consistent with prior
Figure 3. Effect of peptidoglycan modifying enzymes PgdA and Adr on hydrolysis of pneumococcal cell walls in the presence of
lysozyme. Hydrolysis of peptidoglycan (50 mg/ml), purified from the wild-type (WT) strain or the defined mutants indicated with lysozyme (100 mg/
ml) from A) chicken egg (+L) or B) human (+Hu L). Representative experiment showing percentage of hydrolysis based on the optical density (OD
600 nm) of each reaction at time 0 min.
doi:10.1371/journal.ppat.1000241.g003
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respiratory tract samples [6,23]. There was no significant effect of
neutrophil depletion on the presence of lysozyme in lavage
samples from colonized mice. Using immunohistochemistry on
tissue sections through the nasal passages, lysozyme was detected
along the epithelial surface and mucoid material in the nasal
lumen of LysM
+/+, but not LysM
2/2, colonized mice (Fig. 7B). It
was concluded that the epitheilia rather than neutrophils was the
major source of upper airway lysozyme that impacts pneumococ-
cal colonization.
Other effects of cell wall modifications
Our observations showed that individual peptidoglycan modi-
fications have lysozyme-independent effects on both bacterial
fitness during colonization, and on resistance to neutrophil-
mediated killing. This may be due to the effects of peptidoglycan
modifications on other molecules that are attached to or associated
with the pneumococcal cell wall. Specifically, an alteration in
amounts of CPS, which is covalently attached to peptidoglycan
[20], may have dramatic effects on fitness during colonization and
resistance to neutrophil-mediated killing [24,25]. Therefore, we
assessed whether mutations in pgdA and adr change surface
expression of the pneumococcal capsule. A sensitive capture
ELISA was used to quantify amounts of cell-associated CPS
(Fig. 8). In comparison to the WT strain or corrected mutant
(pgdA+adr+), pgdA mutants showed significantly elevated levels of
type 4 CPS. This ,8-fold increase in immunoreactive CPS/mg
total cellular protein could account for PgdA-mediated, lysozyme-
independent effects on killing by neutrophils and enhanced
survival during colonization by the pgdA mutant [26]. These
findings demonstrate that, in addition to their effect on resistance
to lysozyme, peptidoglycan modifications may impact major cell
surface structures linked to the cell wall.
Discussion
Our study demonstrates that host expression of lysozyme effects
bacterial colonization. Specifically, we show that lysozyme is an
important antibacterial factor on heavily colonized mucosal
surfaces such as those lining the upper airway. These findings
extend descriptions of the role of lysozyme in protecting the
normally sterile lower airway [3,8,9]. The in vivo effects of the
enzyme were attributed to lysozyme M, since lysozyme P was not
detected in the upper respiratory tract secretions or tissue staining.
As expected, the ability of bacteria to resist lysozymes’ antibac-
terial properties dictates success at these sites. For the pneumo-
coccus, resistance to human lysozyme in vitro and mouse lysozyme
in vivo is dictated by the synergistic effects of two distinct
modifications to the glycan strands of its cell wall. Even though
Figure 4. Effect of peptidoglycan modifying enzymes PgdA and Adr on viability of pneumococci in the presence of lysozyme. Once
the broth culture of the wild-type (WT) strain or the defined mutants indicated reached mid-log phase, lysozyme (100 mg/ml) was added and viable
counts (CFU/ml) were measured 5 hrs later. Strains tested were in a lytA background to eliminate effects of autolysis. Conditions included A) chicken
egg lysozyme (+L) and B) recombinant human lysozyme (+Hu L) or heat inactivated recombinant human lysozyme (+Hu IL). Graphs are based on four
independent determinations 6S.D. (
* p,0.05).
doi:10.1371/journal.ppat.1000241.g004
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bacterial fitness for colonization in the absence of lysozyme,
together they provide a significant survival advantage when
lysosyme is abundant.
Although two different antibacterial properties have been
ascribed to lysozyme, only its enzymatic muramidase activity
appeared to be relevant to pneumococcal survival. Inactivation of
its muramidase activity by denaturing human lysozyme was
sufficient to completely eliminate its ability to kill S. pneumoniae.
Moreover, the cationic antimicrobial peptide (CAMP) activity of
the human-derived peptide LP9 was ineffective against the
pneumococcus. It remains possible that, as is the case for S.
aureus, other cell wall features of the pneumococcus account for its
resistance to the non-muramidase activity of lysozyme [13,19].
Specifically, D-alanylation of S. pneumoniae cell wall-associated
teichoic acids has been shown to contribute to resistance to
antimicrobials, such as nicin and gallidermin [27]. This would be
consistent with results in S. aureus where D-alanylation contributed
to resistance to several antimicrobials, including lysozyme, and the
peptide LP9 [13]. On the other hand, the pneumococcal strains
generated in this study differed from S. aureus in that acetylation by
Adr (OatA in S. aureus) by itself does not confer sufficient resistance
to the lytic effects of lysozyme [18]. Our study confirmed that Adr
contributes to lysozyme resistance, as had been shown previously
by Criso ´stomo et al [21], although we were only able to show an
effect of the O-acetyltransferase Adr in conjunction with the N-
deacetylase PgdA. This may have been due in part to differences
between pneumococcal strains; Criso ´stomo et al used an
unencapsulated laboratory strain, while our studies were conduct-
ed using a clinical isolate. The extent to which these strains
acetylate peptidoglycan residues could be different, and might
account for the limited role of Adr in lysozyme resistance observed
in this study.
Our results are also based on testing of mammalian rather than
chicken egg enzyme, which may have more potent muramidase
activity. This may be due in part to slightly different amino acid
residues present in the catalytic cleft of each enzyme [28,29,30].
The amino acid sequences of chicken egg and human lysozyme
are 57% identical and 76% similar by sequence comparison
(blastp), whereas lysozyme M and human lysozyme are 76%
identical and 86% similar. Although these differences in sequence
do not lead to alterations in protein structure [28], they could
affect affinity for substrates, which could lead to the observed
difference in enzymatic activity.
Although many species modify their peptidoglycan by either O-
acetylation or N-deacetylation, few organisms have thus far been
Figure 5. Effect of peptidoglycan modifying enzymes PgdA and Adr on relative fitness during murine colonization in the presence
and absence of lysozyme M. LysM
+/+ and LysM
2/2 mice were challenged with equal inocula of the wild-type (WT) strain or revertant and the
defined mutant indicated, and the density of each strain was determined in upper respiratory tract lavages 3 days post-inoculation. Each symbol
represents the competitive index value for an individual animal. The competitive index was calculated based on the ratio of mutant to WT bacteria in
nasal lavages compared to the ratio of mutant to WT bacteria in the inoculum. The dotted line is at a value of one; a value greater than one indicates
the mutant out-competes the WT, a value less than or equal to one indicates the WT out-competes the mutant. A) pgdAadr vs. WT (
*** p=0.001). B)
pgdAadr vs. the revertant (pgdA+ adr+)(
** p=0.004). C) pgdA vs. WT. D) adr vs. WT.
doi:10.1371/journal.ppat.1000241.g005
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pneumoniae, these include Bacillus cereus and Lactobacillus fermentum
[32,33,34,35]; both O-acetylation and N-deacetylation have also
been associated with lysozyme resistance, however the combined
effects of both modifications in these organisms has not been
determined. Our results for S. pneumoniae suggest that both
modifications may be needed for full resistance to lysozyme. The
aggregate effects of bacterial surface modifications that affect
lysozyme resistance other than O-acetylation and N-deacetylation
have also not been explored.
An additional observation was that peptidoglycan modifications
affect characteristics of the bacterial cell apart from its resistance to
lysozyme. In particular, we show that mutation of pgdA is sufficient
to alter growth characteristic dictated by its endogenous amidase
(LytA) and to markedly increase levels of cell-associated CPS.
PgdA cleaves an amide bond leaving a charged amino group on
glucosamine residues of the glycan backbone [10]. Mutation of
Figure 6. The contribution of lysozyme from neutrophils to
survival and colonization of mutants lacking peptidoglycan
modifications. A) Neutrophils isolated from human blood were
incubated with serum opsonized bacteria and survival was assessed
following a 45 min incubation. Percent survival was calculated based on
viable counts (CFU/ml) relative to no neutrophil controls. (
*** p,0.001).
B) Neutrophils were depleted with anti-Ly6G antibody RB6-8C5 prior to
challenge with an equal inoculum of pgdAadr and wild-type (WT)
strains. Controls received rat IgG. Two days post-inoculation nasal
lavages were obtained to quantify the competitive index. (
** p,0.01).
doi:10.1371/journal.ppat.1000241.g006
Figure 8. Effect of peptidoglycan modifying enzymes PgdA
and Adr on expression of capsular polysaccharide (CPS).
Sonicates of the bacterial strain indicated were used in a capture ELISA
to measure the amount of cell-associated type 4 CPS produced relative
to the total amount of protein. Values are relative to a standard with
purified type 4 CPS and based on four independent determinations
6S.D. (
* p,0.05,
** p,0.01).
doi:10.1371/journal.ppat.1000241.g008
Figure 7. Expression of lysozyme M in the mouse nasopharyx. A) Western blot of nasal lavages from mice colonized with the wild-type strain
for two days incubated with antisera to lysozyme M. Lane 1: LysM
+/+, rat IgG control. Lane 2: LysM
+/+, neutrophil depletion with mAb RB6-8C5. Lane 3:
LysM
2/2. Size markers are in kilodaltons. B) Immunohistochemistry on paraffin-embedded tissue sections through the nasal tissue 24 hrs post-
inoculation with the wild-type strain. Staining with i) anti-lysozyme M (LysM
+/+), ii) no primary antibody control (LysM
+/+), and iii) anti-lysozyme M
(LysM
2/2). Sections were counterstained with hematoxylin. Magnification 4006.
doi:10.1371/journal.ppat.1000241.g007
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which could impact molecules attached to and associating with
peptidoglycan. The efficiency of attachment of anionic type 4
CPS, which is covalently bound to the surface [20], could be
affected by this difference in charge. Similarly, it would be
interesting to determine if peptidoglycan modifications affect other
cell surface structures such as wall teichoic acid (C-polysaccharide),
which is also covalently attached to peptidoglycan, albeit at a
different position [20]. An increase in cell-associated CPS, or other
effects on the cell surface, could inhibit phagocytosis and explain
the decreased killing of the pgdA mutants by human neutrophils.
Altered cell surface characteristics of pgdA and adr mutants could
also account for their increased fitness during colonization in the
absence of lysozyme. Vollmer et al. previously reported that a pgdA
mutant was less virulent in a pneumococcal model of bloodstream
infection – a result that would seem to be at odds with their
decreased killing by neutrophils and increased fitness on the
mucosal surface [22]. Mutants in pgdA generated in our study,
however, showed attenuated growth in human serum compared to
the WT strain (data not shown). This demonstrates the potentially
pleomorphic and complex effects of peptidoglycan modification on
bacterial growth and survival in different environments. It would
be interesting to determine whether the expression of peptidogly-
can modifying enzymes is differentially regulated under conditions
where the requirement for lysozyme resistance may vary.
Mucosal lysozyme may have direct effects on colonization
through its ability to lyse pneumococci that do not express PgdA
and Adr. Alternatively, degradation of peptidoglycan could release
bacterial products recognized by the host which enhance
inflammation, and indirectly stimulate bacterial clearance. These
inflammatory mediators may include muramyl dipeptide (MDP),
which signals through the nucleotide-binding oligomerization
domain protein 2 (Nod2) cytoplasmic pathway [36,37]. Adr could
affect both sensitivity to lysozyme and signaling triggered by MDP
since its MurNAc component would be modified by acetylation. In
this regard, peptidoglycan modifications have been shown to effect
signaling through Nod1, which recognizes the meso-diaminopime-
lic acid (meso-DAP) fragment of the cell wall [38,39], in response to
Listeria monocytogenes [16]. The relative contributions to pneumo-
coccal clearance of the lytic versus inflammatory effects of
lysozyme, and the effects of peptidoglycan modifications on the
latter, have not yet been explored.
In summary, the host uses lysozyme to target a conserved
feature of peptidoglycan, the glycosidic bond between MurNAc
and GlcNAc. To counter this host defense mechanism, the
pneumococcus modifies both of these residues to decrease
hydrolysis of the bond that links them, despite a significant fitness
cost associated with altering the glycan backbone of its cell wall.
Our findings demonstrate that the peptidoglycan degrading
activity of lysozyme exerts a substantial selective pressure on
residents of mucosal surfaces.
Materials and Methods
Bacterial strains and growth conditions
All strains were created in a type 4 background; using a clinical
isolate and genome-sequenced strain TIGR4 [40]. Pneumococci
were grown in semisynthetic casein plus yeast extract (C+Y) broth,
pH 6.8, at 37uC without agitation or on tryptic soy agar (TSA)
plates supplemented with catalase (5,000 U/plate; Worthington,
Lakewood, NJ) at 37uCi n5 %C O 2. TSA was supplemented with
neomycin (5 mg/ml), spectinomycin (100 mg/ml), or kanamycin
(200 mg/ml) where indicated. Strains were also co-cultivated
under these conditions to ensure there were no effects of one strain
on growth of the other in vitro. For genetic transformations,
bacteria were grown from a low inoculum in C+Ya t3 7 uCt oa n
OD 620 nm of 0.15. Fifty-ml aliquots were added to 950 mlC +Y
pH 8 with 10 ng/ml of synthetic competence-stimulating peptides
1 and 2, 10 ml of 100 mM CaCl2, and approximately 100 pg/ml
of DNA. Reactions were incubated at 30uC for 40 minutes and
then transferred to 37uC for an additional 90 minutes before being
plated on selective medium.
Generation of mutant and revertant strains
pgdA mutant strains. The 59 end of pgdA was amplified using
primers 1 and 2 (primer 1: 59-TGTAGTCTGAGAAGACTTGG-
TAGG-39,p r i m e r2 :5 9-ATTATTTCCTTCCTCTATTTATA-
TCAT-39), the 39 end of pgdA was amplified using primers 3 and 4
(primer 3: 59-GATGAATTGTTTTAGGCAAGAAAAAA-39,
primer 4: 59-ATAAATGATAAGAATCTAAGACCGC-39). A
kanamycin resistance cassette was obtained from the Janus cassette
[41] using primers 5 and 6 (primer 5: 59-AGAGGAAGGAAA-
TAATAAATGGCTAA-39,p r i m e r6 :5 9-CTAAAACAATTCAT-
CCAGTAAAATATA-39). Primers 2 and 3 were designed with
sequences complementary to primers 5 and 6 respectively, to allow
for correct orientation of the kanamycin resistance cassette in
between the flanking regions of pgdA. PCR products generated with
these primers were purified using the QIAquick PCR purification kit
(Qiagen Sciences, Germantown, MD) and incubated together in an
overlap extension PCR. The reaction conditions were as follows:
denaturation at 94uC for 2 min, 2 cycles of denaturation at 92uCf o r
30 sec, annealing at 40uC for 1 min, and extension at 68uCf o r
7m i n ,3 3c y c l e so fd e n a t u r a t i o na t9 2 uC for 30 sec, annealing at
55uC for1 min, extensionat 68uCfor 7 min, anda final extension at
68uCfor8 min.PCRproductswerethenusedinatransformationas
described above with selection for kanamycin resistance. Mutant
pgdA strains were confirmed by PCR with primers 1 and 4 followed
by sequencing of the product.
adr mutant strains. The 59 end of adr was amplified using
primers 7 and 8 (primer 7: 59-CAGATTCACCAATCAAATAT-
CGTTTG-39, primer 8: 59-GAACGAAAATCGAATCAAGGA-
AAACCATTTAATGCGC-39), the 39 end of adr was amplified
using primers 9 and 10 (primer 9: 59-CCCTTGCATATTGCA-
GACAGCTCCAGACAAGCC-39, primer 10: 59-TTCGTGGC-
CAAGAATGGTACCAC-39), and a spectinomycin resistance
cassette from plasmid pJL74 [42] was amplified using primers
11 and 12 (primer 11: 59-TTTTCCTTGATTCGATTTTCGT-
TCGTGAATAC-39, primer 12: 59-AGCTGTCTGCAATA-
TGCAAGGGTTTATTGTTTTC-39). Primers 8 and 9 were
designed with sequences complementary to primers 11 and 12
respectively, to allow for correct orientation of the spectinomycin
resistance cassette in between the flanking regions of adr. Overlap
extension and transformations were performed as described above,
with adr colonies selected by resistance to spectinomycin resistance.
Mutant adr strains were confirmed by PCR with primers 7 and 10
followed by sequencing of the product.
Additional mutant strains. To generate the pgdAadr mutant,
lysate from the pgdA strain was transformed into the adr
background, and mutations were confirmed as described above.
lytA mutants were created using lysates from pgdA, adr, and pgdAadr
strains and transformed into a non-autolytic TIGR4 mutant with a
spontaneous deletion within lytA [43]. lytA mutant strains were
confirmed with primers 13 and 14 (primer 13: 59-
GCGCGGATCCCTTTTTAGTCTGGGGTG-39, primer 14:
59-GCGCCTGCAGATGACAAAACAAGGAA-39).
Revertant strains. Revertant strains were created by
transforming the pgdAadr mutant with WT lysate, followed by
serial passage in chicken egg lysozyme (100 mg/ml) to select for
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and a mutant adr gene, while the pgdA+adr+ strain is parental in
both the pgdA and adr genes. Colonies were patched onto plates
containing kanamycin or spectinomycin and the genotype of those
that had lost resistance was confirmed by PCR as described above.
In vitro lysozyme sensitivity
Bacterialgrowthofbrothcultureswasmeasured byopticaldensity
at an absorbance of 620 nm. Chicken egg white (Sigma, St. Louis,
MO) or recombinant human lysozyme (Ventria Bioscience, Fort
Collins, CO) was added to PBS at a stock concentration of 10 mg/
ml. Broth cultures at mid-log phase (OD 620 nm=0.3) were divided
and received either lysozyme (100 mg/ml) or vehicle control. Where
specified, lysozyme from the stock solution was inactivated by
treatment at 100uC for 60 min. LP9, a synthetic human lysozyme-
derived peptide (107R-A-W-V-A-W-R-N-R115) (GenScript Corpo-
ration, Piscataway, NJ), was used at a concentration of 200 mg/ml.
Following addition of lysozyme,growth wasmonitored for5 hrs.For
viable counts an aliquot was removed and serial dilutions plated.
Mean bactericidal concentrations (MBC50) were estimated by
treating mid-log phase lytA mutant strains with recombinant human
lysozyme. 10
2 bacterial cells were resuspended in Hank’s buffer with
Ca
2+ and Mg
2+ (Gibco, San Diego, CA), and 0.1% gelatin (+++
solution), and were incubated with varying concentrations of human
lysozyme: 180 mg/ml, 100 mg/ml, 50 mg/ml, 25 mg/ml, or
12.5 mg/ml. Reactions were incubated for 60 min at room
temperature, and then plated to determine viable counts. MBC50
values were determined based on viability relative to reactions at
time 0 min, and relative to no treatment controls.
To purify cell walls of pneumococci, cultures were first grown to
exponential phase as described above. Cell walls were then purified
as previously described [18]. Two-mg of crude cell walls were
resuspended in 1 ml of solution (100 mM Tris Buffer pH 7.5,
10 mM CaCl2,a n d1 0 0mg trypsin) and incubated overnight at
37uC with agitation. Trypsin was inactivated by incubation at 65uC
in 1% sodium dodecyl sulfate (SDS). Cell walls were then washed
three times in distilled water to eliminate SDS and resuspended in
dH2O to an OD 600 nm=0.6. Hydrolysis was measured by the
decline in absorbance (OD 600 nm) over 120 min in the presence of
lysozyme (100 mg/ml). Percentage of hydrolysis was expressed
relative to the absorbance of each sample at time 0 min.
Murine model of bacterial competition
Six to 8-week-old female FVB/NJ mice were obtained from
Jackson Laboratories, Bar Harbor, ME. Lysozyme deficient mice
(LysM
2/2) were generated in the FVB/NJ background (by T.
Graf) by insertion of the Enhanced Green Fluorescent Protein into
exon 1/intron 1 of the lysozyme locus. LysM
2/2 mice were
backcrossed through ten generations into the FVB/NJ background
[3,44]. Animals were housed in accordance with Institutional
Animal Care and Use Committee protocols. All strains were
animal passaged prior to use in experiments and stored at 280uC
in 20% glycerol. Inocula consisted of a total of 10
7 mid-log phase
PBS-washed bacteria in 10 ml PBS (5610
6 WT or revertant cells
plus 5610
6 mutant cells). Inocula were plated onto the appropriate
selective media to confirm the concentration of each strain. Three
days after intranasal inoculation, mice were sacrificed, the trachea
cannulated, and 200 ml of PBS was instilled. Lavage fluid was
collected from the nares and serially diluted in PBS. Total
pneumococci were enumerated by plating onto media supple-
mented with neomycin to prevent the growth of contaminants.
Selective media was used to quantify the proportion of WT or
revertant vs. mutant bacteria in lavages. The lower limit of
detection was 20 CFU/ml of lavage fluid.
Phagocytic killing assays
Neutrophils were isolated from human blood by density
centrifugation on a Ficoll gradient using Mono-Poly Resolving
Medium according to the manufacturer’s instructions (MP
Biomedicals, Irvine, CA). The neutrophil-enriched fraction was
collected and washed with Hank’s buffer without Ca
2+ or Mg
2+
(Invitrogen, Carlsbad, CA) with 0.1% gelatin. Cells were counted
using trypan blue staining and adjusted to a density of 7610
6
cells/ml in Hank’s buffer with Ca
2+ and Mg
2+ (Gibco, San Diego,
CA), and 0.1% gelatin (+++ solution). Bacterial strains were grown
to mid-log phase, PBS-washed, and resuspended in +++ solution.
10
2 bacterial cells (in 10 ml) were pre-opsonized with infant rabbit
serum (40 ml) (Pel-Freez, Rogers, AR) for 30 mins at 37uC with
rotation. Neutrophils were then added to reactions (10
5 cells per
reaction in 40 ml) with +++ solution (110 ml) and incubated 45 min
at 37uC with rotation. Reactions were stopped by incubation at
4uC, neutrophils were lysed with dH2O, and viable counts of
bacteria were determined. Percent survival was determined
relative to control reactions lacking neutrophils.
Neutrophil depletion
Monoclonal antibody (mAb) RB6-8C5, a rat anti-mouse IgG2b
directed against Ly-6G on the surface of murine myeloid (and
limited subpopulations of lymphoid) lineage cells, was purified
from ascites of nude mice given the RB6-8C5 hybridoma [45,46].
To deplete neutrophils, 145 mg of mAb/animal was given by
intraperitoneal (i.p.) injection 24 hours prior to intranasal
challenge with bacteria. This dose was previously shown to result
in peripheral blood neutropenia (,50 granulocytes/ml) for a
period of at least 48 hours [47]. Controls were given the
equivalent i.p. dose of total rat IgG (Sigma, St. Louis, MO).
Western blot analysis
Mice were colonized 48 hrs with WT S. pneumoniae, sacrificed, and
nasal lavages obtained as described above. Nasal lavage fluid was
separatedbySDS-polyacrylamide gelelectrophoresisona 15%Tris-
HCl gel (Bio-Rad, Hercules, CA), and proteins were transferred to a
polyvinylidene difluoride transfer membrane (Thermo Scientific,
Rockford, IL). Murine lysozyme was detected using a rabbit anti-
mouse polyclonal IgG antibody to recombinant lysozyme M [6] and
detected with enhanced chemiluminescent (ECL) anti-rabbit IgG
horseradish peroxidase-conjugated secondary antibody from donkey
(GE Healthcare, Little Chalfont, Buckinghamshire, UK). Secondary
binding was detected with ECL Western Blotting Substrate (Pierce
Biotechnology, Rockford, IL).
Immunohistochemistry
Mice were colonized 24 hrs with WT S. pneumoniae, a time point
prior to neutrophil influx into the nasopharynx. Mice were then
sacrificed, decapitated, and heads were fixed in 4% paraformal-
dehyde in PBS for 48 hrs. Heads were then decalcified for 24 hrs
in Cal-EX decalcifying solution (Fisher Scientific, Fair Lawn, NJ).
Paraffin-embedded tissue was sectioned and rehydrated through a
series of xylene and ethanol washes with decreasing concentrations
of ethanol. Sections were post-fixed in 1:1 methanol-acetone at
220uC for 10 min followed by washing in distilled water (dH20).
Endogenous peroxidases were blocked with 30% hydrogen
peroxide in dH20 for 15 min. Sections were also blocked with
avidin and biotin, each for 15 mins, followed by a 10 min
incubation in protein blocking reagent (Coulter/Immunotech,
Miami, FL). Murine lysozyme was detected using a rabbit anti-
mouse polyclonal IgG antibody to recombinant lysozyme M [6] at
a 1:500 dilution in PBT (16 PBS, 0.1% bovine serum albumin,
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controls, and incubated 60 min at 37uC. Primary antibody was
detected using a biotinylated goat anti-rabbit antibody (Vector
Laboratories, Burlingame, CA) with a 1:200 dilution in PBT and
incubated 30 min at 37uC, followed by 30 min incubation at 37uC
with horseradish peroxidase-conjugated ABC reagent (Vector
Laboratories). Sections were washed with PBS between all steps.
The signal was developed using a diaminobenzidine tetrahy-
drochloride (DAB) kit (Vector Laboratories) and developing was
stopped with dH20. Sections were then counterstained with
hematoxylin, dehydrated in ethanol, cleared in xylene, and
mounted in Cytoseal (Richard-Allen Scientific, Kalamazoo, MI).
ELISA for capsular polysaccharide (CPS)
Cultures of strains of the same colony opacity were grown to
stationary phase in 10 ml of C+Y, pelleted, and resuspended in
10 ml of PBS. Cells were adjusted to equal optical density,
resuspended in 1 ml of PBS, and lysed by sonication. Capture
ELISAs were then used to quantify capsule as previously described
[24]. Type 4 typing sera (Statens Seruminstitut, Copenhagen, DK)
was fixed to a 96-well polystyrene microtiter plate by incubating
16 hours at room temperature (RT) using a 1:5000 dilution in
0.05 M sodium carbonate. Plates were washed five times with
wash buffer (16 PBS with 0.05% Brij). Sonicate samples were
added at a 1:500 dilution and plates were incubated 2 hrs at RT
with agitation, followed by five washes. A mAb to type 4 CPS was
added at 1:400 dilution in wash buffer. Goat anti–mouse IgG
alkaline phosphatase conjugate was used as the secondary
antibody at a dilution of 1:10,000. Both antibodies were incubated
in plates for 2 hrs at RT with agitation followed by five washes.
Plates were developed using alkaline phosphatase substrate
(Sigma, St. Louis, MO) in diethanolamine buffer, and were read
at an absorbance of 415 nm. Total protein in each sonicate was
measured using a Micro-BCA protein assay kit (Pierce Biotech-
nology, Rockford, IL), following the manufacturer’s protocol.
Purified type 4 CPS (American Type Culture Collection,
Manassas, VA) was used as a standard.
Statistical analysis
Statistical comparisons of lysozyme sensitivity, phagocytic killing
assays, and amounts of CPS were calculated using a 1-way
ANOVA (Kruskall-Wallis test, non-parametric) with Dunn’s post-
test (Prism 4, GraphPad Software, San Diego, CA). Statistical
comparisions between colonization groups were computed using
the Mann-Whitney test (non-parametric, two-tailed test) (Prism 4,
GraphPad Software, San Diego, CA).
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